Recovery research fieldbook Evidence, not treatment advice
Recovery archive

Published recovery field note

Human Myostatin Propeptide Recombinant Protein (120

Gibco Additional Information: {{banner.description}} Product Details 120-12-25UG Applications Tested Dilution Publications Control (Ctrl) Assay-dependent - Western blot control (WB Ctrl) - Bioactivity (Bioactivity) Assay-dependent - Product Specifications Species Human Published species Human Expression System E. coli Amino acid sequence MNENSEQKEN VEKEGLCNAC TWRQNTKSSR IEAIKIQILS KLRLETAPNI SKDVIRQLLP KAPPLRELID QYDVQRDDSS DGSLEDDDYH ATTETIITMP TESDFLMQVD GKPKCCFFKF SSKIQYNKVV KAQLWIYLRP VETPTTVFVQ ILRLIKPMKD GTRYTGIRSL KLDMNPGTGI WQSIDVKTVL QNWLKQPESN LGIEIKALDE NGHDLAVTFP GPGEDGLNPF LEVKVTDTPK RSRR Molecular weight 27.8 kDa Class Recombinant Type Protein Purity ≥ 98% by SDS-PAGE gel and HPLC analyses. Endotoxin concentration <1 EU/μg Activity Determined by its ability to neutralize the Myostatin inhibitory effect of murine MPC-11 cells. The expected ED50 is 0.01-0.04 ug/ml in the presence of 50 ng/ml Myostatin. Conjugate Form Lyophilized Amount 25 μg Purification purified Contains n

Context first

Study findings do not automatically establish clinical benefit, safety, dosing, or suitability for an individual.

Gibco

Additional Information:

{{banner.description}}

Product Details

120-12-25UG

Applications

Tested Dilution

Publications

Control (Ctrl)

Assay-dependent

-

Western blot control (WB Ctrl)

-

Bioactivity (Bioactivity)

Assay-dependent

-

Product Specifications

Species

Human

Published species

Human

Expression System

E. coli

Amino acid sequence

MNENSEQKEN VEKEGLCNAC TWRQNTKSSR IEAIKIQILS KLRLETAPNI SKDVIRQLLP KAPPLRELID QYDVQRDDSS DGSLEDDDYH ATTETIITMP TESDFLMQVD GKPKCCFFKF SSKIQYNKVV KAQLWIYLRP VETPTTVFVQ ILRLIKPMKD GTRYTGIRSL KLDMNPGTGI WQSIDVKTVL QNWLKQPESN LGIEIKALDE NGHDLAVTFP GPGEDGLNPF LEVKVTDTPK RSRR

Molecular weight

27.8 kDa

Class

Recombinant

Type

Protein

Purity

≥ 98% by SDS-PAGE gel and HPLC analyses.

Endotoxin concentration

<1 EU/μg

Activity

Determined by its ability to neutralize the Myostatin inhibitory effect of murine MPC-11 cells. The expected ED50 is 0.01-0.04 ug/ml in the presence of 50 ng/ml Myostatin.

Conjugate

Form

Lyophilized

Amount

25 μg

Purification

purified

Contains

no preservative

Storage conditions

-20°C

Shipping conditions

Ambient

Product Specific Information

Recombinant Human Myostatin-Propeptide is a 27.8 kDa protein consisting of 244 amino acid residues.

This product is shipped at ambient temperature. For storage, handling and reconstitution information, please see the lot-specific Certificate of Analysis

Target Information

Mature myostatin is obtained by proteolytic processing of a biologically-inactive precursor protein, which contains an N-terminal propeptide of 243 amino acid residues. Myostatin-Propeptide exhibits high binding affinity for myostatin, and has been shown to be a potent inhibitor of myostatin. Over-expression of myostatin-propeptide in mice resulted in large increases (up to 200%) in skeletal muscle mass, similar to those observed in myostatin knockout mice.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

Bioinformatics

Protein Aliases: myostatin-b; transforming growth factor-beta superfamily member; unnamed protein product

View more View less

It has to be done as per old AB suggested Products section.

Connected topics

Follow this recovery question